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Abstract
Although many animal viruses block the interferon (IFN) signaling pathway, this issue has not been previously investigated in retrovirus-infected
cells. For this purpose, an infectious molecular clone of human T-cell leukemia virus type 1 (HTLV-1) was transfected into 293T or HeLa cells and
was found to reduce interferon-stimulated response element (ISRE) reporter activity. This effect was independent of expression of the polymerase or
envelope products and independent of the ability of Tax to activate the NFκB transcriptional pathway. IFN-α activation of 6 of 7 endogenous ISRE-
regulated genes was also variably reduced, but not IFN-γ-activated response element-mediated expression of interferon regulatory factor 1. HTLV-1
reduced the phosphorylation of tyrosine kinase 2 (TYK2) and signal transducer and transcriptional activator 2 (STAT2), suggesting a specific effect of
HTLV-1 on the ability of an adaptor tyrosine kinase to transfer an IFN signal to the STAT–transcriptional activator complex.
© 2008 Elsevier Inc. All rights reserved.Keywords: HTLV; Type I interferon; STAT2; TYK2; GagIntroduction
Interferons were discovered 50 years ago as proteins that
inhibit virus replication. Type I interferons (IFN), IFN-α and
IFN-β can be produced in a wide range of cell types, whereas
type II IFN-γ is largely produced by T lymphocytes, NK, and
dendritic cells (reviewed in Brierley and Fish, 2005; vanBoxel-
Dezaire et al., 2006; Wesoly et al., 2007). IFN signaling is
initiated by binding to heterodimeric cell surface proteins (Fig. 1).
This results in the activation of Janus kinases, which, in the case
of type I IFN, include Janus kinase 1 (JAK1) and tyrosine kinase
2 (TYK2). This causes phosphorylation of the signal transducer
and activator of transcription 1 (STAT1) and STAT2, which
complexes with interferon regulatory factor 9 (IRF9) to form the
interferon-stimulated gene factor 3 (ISGF3). ISGF3 then translo-
cates into the nucleus, binds, and activates interferon-stimulated
response element (ISRE)-containing genes, such as interferon-
stimulated gene 15 (ISG15), myxovirus resistance gene A (MxA),
interferon-inducible gene 6–16 (GIP3), and the genes for protein
kinase R (PKR), guanylate nucleotide-binding protein 1 (GBP1),
IFN-α-inducible gene 27 (IFI27), and 2′,5′-oligoadenylate syn-⁎ Corresponding author. Box 8069, 660 S Euclid Ave, St Louis, MO 63110,
USA. Fax: +1 314 747 2120.
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doi:10.1016/j.virol.2007.12.036thetase 1 gene (OAS). Alternatively, through the JAK1/JAK2
pathway, phosphorylated STAT1 homodimers directly activate
IFN-γ-activated (GAS) genes, such as IRF1.
The mechanism of action of IFN on retroviruses is poorly
understood. Okumura et al. (2006) showed that IFN-α blocks
HIV-1 release mediated by the ubiquitin ligase, ISG15. We have
also found that IFN-α blocks release of HTLV-1 particles, by
inhibiting Gag targeting to lipid rafts (Feng et al., 2003). Thus,
the critical HTLV-1 mediator of IFN-α action appears to be the
gag gene product.
Viruses have developed various mechanisms for initiating
virus replication in the host by disrupting the actions of IFN or
evading IFN-stimulated responses (Sen, 2001; Levy and Garcia-
Sastre, 2001; Katze et al., 2002; Garcia-Sastre, 2002). The major
strategies include inhibition of IFN production and secretion,
competition for binding to IFN receptors, degradation or sup-
pression of JAK–STAT components, and inhibition of the ac-
tions of IFN-induced antiviral proteins. The human papilloma
virus type 18 E6 oncoprotein physically associates with TYK2
and impairs JAK–STAT activation by IFN-α (Li et al., 1999).
Flaviviruses also utilize a number of different mechanisms me-
diated by non-structural (NS) proteins to elude IFN responses
(Samuel and Diamond, 2006). For example, Japanese encepha-
litis virus blocks IFN-induced JAK–STAT signaling through
interaction of protein NS5 with a protein tyrosine phosphatase,
Fig. 1. Model of effects of HTLV-1 on IFN-α-induced signal transduction pathways. Data in the current manuscript are consistent with normal interaction of IFN-α and
IFN-β with the heterodimeric IFN receptor at the cell surface. However, activation of signal transduction appears to be reduced by HTLV Gag, particularly through
effects on TYK2 and STAT2 tyrosine phosphorylation. Thus, ISRE-stimulated gene expression through ISGF3, complexes of STAT1 and/or STAT2 proteins with
IRF9 are generally reduced, whereas GAF-stimulated gene expression of IRF1 is largely unaffected by HTLV-1.
Fig. 2. Inhibitory effects of HTLV-1 on type I IFN signaling in 293T cells. 293T
cells were transfected with pLTR-luc or pISRE-luc and pACH (HTLV) or
pBluescript (Control) for 72 h, and then treated for 6 h with 500 U/ml IFN-α or
100 U/ml IFN-β, or left untreated. Cell lysates were examined by luciferase
activity and relative light units (RLU) determined. Means and standard de-
viations are shown for representative assays. All assays were performed in at
least three independent experiments.
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Moreover, West Nile virus, dengue virus, and tick-borne Langat
virus also counteract JAK–STAT signaling by blocking the
phosphorylation of JAK1, TYK2, STAT1, and STAT2 (Best
et al., 2005; Guo et al., 2005; Ho et al., 2005).
A number of other observations about IFN activity during
HTLV infection are also relevant. HTLV-1-infected cells exhibit
constitutive activation of the JAK/STAT pathway (Migone
et al., 1995). Activation of IFN-γ release by HTLV-1 has been
suggested to be important in HTLV-1-associated myelopathy-
tropical spastic paraparesis (HAM/TSP) (Furuya et al., 1999).
IRF4 levels have been shown to correlate with chemotherapy-
resistance of HTLV-1-induced adult T-cell leukemia–lymphoma
(ATLL) (Ramos et al., 2007). HTLV-1 infection of plasmacytoid
dendritic cells results in impaired IFN-α production, and corre-
lates with elevated HTLV-1 proviral load in infected individuals
(Hishizawa et al., 2004). The current work addresses the ques-
tion as to whether HTLV-1 blocks the IFN signaling pathway,
and identifies inhibition of IFN-induced TYK2 and STAT2
activity. Although differences in IFN signaling exist among
different cell types, the current work utilized fibroblast cell lines
as a model system, using cell lines that are highly infectible by
HTLV-1 (Feng et al., 2003; Khabara et al., 2004; Trejo and
Ratner, 2000).
Results
HTLV-1 inhibition of signaling by IFN-α
In order to assess the effects of HTLV-1 on type I IFN sig-
naling, 293T cells were transfected with an infectious HTLV-1molecular clone, pACH, or control plasmid, pBluescript, to-
getherwith luciferase reporter plasmids. After 72 h, the cells were
treated for 6 h with 500 U/ml IFN-α or 100 U/ml IFN-β. In
control cells, IFN-α and IFN-β activated the IFN-stimulated
response element (ISRE) 9.1- and 4.2-fold, respectively (Fig. 2,
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activity to 35% and 44% of control values in IFN-α- and IFN-β-
treated cells, respectively. IFN-α had no significant effect on the
ability of ACH to trans-activate the HTLVLTR promoter (Fig. 2,
bottom panel).
We also investigated the effects of HTLVof IFN-α signaling
in HeLa cells, another cell line sensitive to the effects of type I
interferons (Dave et al., 2006). In these studies, both wild type
and mutant forms of pACH were utilized (Fig. 3A). Similar
results were obtained in IFN-α-treated HeLa cells as described
for 293T cells. IFN-α-stimulated ISRE-luc activity was de-
creased in the presence of pACH to 20% of control (Fig. 3B, lane
M vs. lane 1). Similar results were obtained with a mutant of
pACH, pACH-M22, inwhich the tax gene is mutated to eliminate
its ability to trans-activate theNFκB pathway (pACH-tax-NFκB;
Figs. 3A and B, lane M vs. lane 2) (Robek and Ratner, 1999). In
contrast, a mutant of pACH, pACH-M47, in which the tax gene is
mutated to decrease CREB-ATF activation 25-fold, did not blunt
interferon-stimulated ISRE-luc activity (pACH-tax-CREB;
Figs. 3A and B, lane M vs. lane 3) (Robek and Ratner, 1999).
It should be noted that the lack of CREB–ATF activation by
pACH-M47 also markedly suppresses expression of all HTLV
gene products, including Gag, Pr, Pol, and Env (Fig. 3A).
In order to identify the HTLV gene product responsible for
blunting IFN-α-stimulated ISRE-luc activity, two additional
mutants of pACH were tested. pACH-env includes an amber
mutation at codon 32 of the envelope precursor protein, and fails
to express envelope proteins, but exhibits no defect in the
expression of other HTLV-1 proteins (Fig. 3A) (Tsukahara and
Ratner, 2001). pACH-env blunted ISRE-luc activity to 47% of
that of control IFN-α-treated cells (Fig. 3B, lane M vs. lane 4),Fig. 3. Inhibition of IFN-α signaling in HeLa cells by wild type and mutant HTLV-1 m
clones, including the wild type clones, clones with specific mutations in Tax that blo
expressed at wild type levels are shown with black shadowing, whereas mutant Tax pr
clone, indicated by number referring to A. After 72 h, cells were treated with 500 U/ml
and RLU determined, normalized to that of the mock control. Means and standard dev
three independent experiments. Numbers under bars refer to pACH mutant shown iindicating that env is not responsible for ISRE repression.
pACH-pol includes a frameshift mutation in the spacer between
Pr and Pol, and fails to express Gag-Pr-Pol precursor protein,
although there is no defect in expression of the Gag precursor,
Env, Tax, or Rex (Fig. 3A) (Heidecker et al., 2002). pACH-Pol
repressed IFN-α-induced ISRE-luc activity comparable to that
of wild type pACH (Fig. 3B, lane M vs. lane 5), indicating that
pol is not responsible for ISRE suppression. Therefore, Gag or Pr
is likely responsible for HTLV-1 suppression of ISRE activity.
IFN signaling pathway target of HTLV-1 inhibition
The IFN-α signaling pathway was further dissected by ex-
amining the effects of HTLV-1 on endogenous IFN-α pathway
gene expression profiles. For this purpose, real-time RT–PCR
was performed to assess expression of genes involved in the
IFN-α signaling pathway, and constitutively expressed genes
not affected by IFN-α. Genes with an ISRE were examined,
including OAS, GBP1, and ISG15 (Fig. 4). IFN-α-induced OAS
and GBP1 gene expression were reduced to 16% and 28%,
respectively ( pb .02 by t-test), whereas IFN-α-induced ISG15
gene expression was increased 2.2-fold by HTLV expression,
although not statistically significant ( pb .09). HTLV-1 also had
no significant effect on IFN-α-stimulation of IRF1 ( p=.73),
which is primarily induced by IFN-γ-activated sequence (GAS).
This suggests that IFN-α receptor expression is not altered by
HTLV-1. Several additional ISRE-regulated genes were also
examined by real-time PCR, including IFI27, G1P3, MxA, and
PKR (Fig. 4). In these cases, gene expression was blunted by
HTLV-1 to 33% ( pb .01), 61% (pb .01), 42% ( p=.057), and
86% of control values ( pb .02), respectively.olecular clones. (A) Schematics are provided for each of the HTLV-1 molecular
ck NFκB or CREB signaling, a mutation in Env, or a mutation in Pol. Proteins
oteins are shown with shading. (B) pISRE-luc was co-transfected with each ACH
IFN-α for 6 h, or left untreated. Cell lysates were examined by luciferase activity
iations are shown for representative assays. All assays were performed in at least
n A, whereas M refers to pBluescript-transfected cells.
Table 1
Results of gene expression array examining effects of HTLV-1 and IFN-α in
HeLa cells
HTLV IFN HTLV+IFN
JAK–STAT proteins
JAK1 0.89 0.47 0.86
JAK2 0.29 0.77 0.49
STAT1 0.67 5.76 3.93
STAT2 1.44 6.61 3.93
TYK2 0.89 0.47 0.69
Receptors that bind and active JAK proteins
CSF1R 0.12 1.54 0.56
GHR 0.07 2.18 0.80
IFN-γR1 0.25 0.95 0.69
IL10RA 2.03 4.07 1.30
SH3/SH2 adaptor proteins
SH2B 0.77 0.83 0.40
SIT1 0.11 2.18 0.56
SRC 0.58 0.27 0.23
STAT1-inducible genes
CXCL9 0.10 3.08 1.30
IRF1 3.08 5.37 6.39
STAT3-inducible genes
CDKN1A 1.90 1.02 2.26
CRP 0.16 3.31 0.98
IRF1 3.08 5.37 6.39
SOCS1 0.89 13.22 7.86
STAT4-inducible gene
IRF1 3.08 5.37 6.39
STAT5-inducible genes
CCND1 0.24 0.24 0.40
CDKN1A 1.90 1.02 2.26
IRF1 3.08 5.37 6.39
OSM 0.14 3.08 0.80
STAT6-inducible genes
GATA3 0.24 2.34 0.80
FcεR1 0.04 1.90 0.69
IL4 0.05 2.88 0.92
STAT1/STAT1/IRF9-inducible genes
GBP1 4.36 184.18 51.09
STAT1/STAT2/IRF9-inducible genes
ISG15 5.01 9.35 20.75
OAS 1.44 37.40 11.92
Inhibitors of JAK/STAT pathway
SOCS1 0.89 13.22 7.86
SOCS2 0.25 1.54 0.98
SOCS4 0.83 0.83 0.49
Levels of eachmRNA in cells treated for 2 hrswith 1000U/ml IFN-α or untreated
cells were determined by real-time RT–PCR, normalized to 5 housekeeping
genes, and then normalized to values obtained in HeLa cells transfected with
pBluescript and not treated with IFN-α.
Fig. 4. HTLV-1 inhibition of IFN-α-stimulated gene expression. pACH-
transfected HeLa cells were cultured for 72 h, and then 500 U/ml IFN-α was
added for 4 h, or cells were left untreated. Total cellular RNA was isolated
subjected to quantitative real-time RT–PCR using primers for each of the
indicated genes. Means and standard deviations are shown for triplicate
measurements performed with primers for IFI27, GIP3, MxA, and PKR,
although standard deviations for the latter two genes were too low to be
visualized on the graph. Results are shown as the proportional increase over that
present in control HeLa cells not treated with IFN. Results from PCR
SuperArray profiles for OAS, GBP1, ISG15, and IRF1 are also graphed.
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signaling, were also evaluated by real-time RT–PCR (Table 1).
These included JAK–STAT proteins, receptors that bind active
JAK proteins, SH3/SH2 adaptor proteins, STAT-inducible
genes, and inhibitors of the JAK/STAT pathway. Several of
these genes were activated by IFN-αmore than 4-fold, including
STAT1, STAT2, IL-10 receptor-α (IL10RA), and the suppressor
of cytokine signaling 1 (SOCS1), and in each case, HTLV-1
blunted IFN-α-induced gene expression within the range of 1.4-
to 3.1-fold ( pb .07 by t-test for STAT1, and pb .05 for the other
genes). Expression of several genes was altered by HTLV more
than 4-fold in the absence of IFN-α, including induction of ISG15,
and reduced expression of CSF1R, growth hormone receptor
(GHR), IFN-γ receptor 1 (IFN-γR1), adaptor SIT1, chemokine
CXCL9, C-reactive protein (CRP), cyclin D1 (CCND1), onco-
STATin M (OSM), transcription factor GATA3, Fc-γ receptor 1
(Fc-γR1), IL4, and suppressor of cytokine signaling 2 (SOCS2).
IFN-α signaling is initiated by binding to the heterodimeric
IFN-α receptor, activation of JAK1 and TYK2 protein kinases,
resulting in the phosphorylation of STAT1 and STAT2, which
then interact with IRF9 to translocate as a complex into the
nucleus to activate ISRE transcription. Immunoblots were used
to examine phosphorylation of these critical mediators of IFN-α
activity and were compared to the immunoblots of the total level
of the corresponding protein as well as that of actin (Fig. 5).
These studies were carried out for 1 h after IFN-α treatmentin order to focus on early phosphorylation events. IFN-α-
induced phosphorylation of STAT1 was detected at only low
levels (1.49-fold), and effects of HTLV were limited. In con-
trast, IFN-α induced phosphorylation of STAT2 19.5-fold, but
only 5.49-fold in the presence of HTLV. Only limited IFN-α
induction of JAK1 phosphorylation was noted (1.32-fold), but
IFN-α induced phosphorylation of TYK2 4.7-fold, but only
1.26-fold in the presence of HTLV. There was very little effect
of HTLV or IFN-α on total STAT1, STAT2, JAK1, and TYK2
protein levels, over the time course of this experiment. In this
study, immunoblots were also performed for IRF1, IRF9, and
Fig. 5. HTLV-1 inhibition of IFN-α-induced tyrosine phosphorylation of TYK2
and STAT2. pACH (HTLV) or pBluescript-transfected HeLa cells (CON) were
cultured for 72 h, and treated with 1000 U/ml of IFN-α for 1 h, or left untreated.
The cell lysates were examined by immunoblots with antibodies to Tyr-701-
phosphorylated STAT1, STAT1, Tyr-689-phosphorylated STAT2, STAT2, Tyr-
1022/1023-phosphorylated JAK1, JAK1, Tyr-1054/1055-phosphorylated TYK2,
and TYK2. In addition, immunoblots are shown for IRF1, IRF9, PKR, and actin.
Band intensities were determined by densitometry, and ratios of band intensities
for phosphorylated compared to total protein levels are presented. Similar results
were obtained in at least two different experiments for all of the proteins shown.
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with HTLV or 1 h of IFN-α treatment.
Discussion
IFN-α blocks HTLV-1 replication by inhibiting virus assem-
bly and release, rather than viral protein synthesis as shown for
many other types of animal viruses (Feng et al., 2003). This
effect is a result of inhibition of Gag targeting to lipid rafts. It is
unclear whether this is due to an effect of IFN-α on the protein
or lipid composition of rafts, an effect of IFN-α on a chaperone
protein, or an effect on a post-translational modification of Gag
required for interaction with rafts. In the current, work, we
found that HTLV-1 also partially blunts signaling by IFN-α, as
well as IFN-β (Fig. 2). This effect is likely mediated by the Gag
protein, although we cannot fully exclude effects due to viral
protease or virion RNA (Fig. 3). Perhaps HTLV-1 Gag perturbs
the lipid raft environment critical for type I IFN signaling to
STAT1 and STAT2 (Marchetti et al., 2006).
Studies of effects of HTLV-1 on IFN-α responses showed
that ISRE-containing gene expression is generally reduced by
HTLV-1, although to a variable extent. It is notable that HTLV-1
repressed exogenous ISRE-containing gene expression to a si-
milar extent whether or not IFN was added (Figs. 2 and 3). In
contrast, endogenous ISRE-containing gene expression was re-
pressed only in the presence of IFN (Fig. 4 and Table 1). Perhaps,
plasmid transfection activated endogenous IFN production.
IFN-α-stimulated expression of IFI27, GIP3, MxA, PKR,
GBP1, and OAS were reduced by HTLV-1 by 39–74%, whereasIFN-α-stimulated expression of PKR was reduced by b15%
(Fig. 4). Moreover, IFN-α-stimulated expression of ISG15 was
mildly stimulated by HTLV-1. Effects on ISG15 were likely
related to the fact that HTLV-1 directly stimulates ISG15, in the
absence of IFN-α (Table 1) (Ruckes et al., 2001). These dif-
ferences may relate to differences in binding affinities of ISGF3
complexes based on differences in ISRE sequences within each
of these genes, or differences in effects of HTLV-1 on STAT-1 vs.
STAT-2, or other STAT proteins (Kovarik et al., 2001; Wesoly
et al., 2007). The latter explanation is consistent with the finding
that HTLV-1 had no effect on IFN-α-stimulated IRF1 expression
mediated by the GAS response element, which preferentially
binds STAT1 homodimers (Wesoly et al., 2007).
We also explored the steps in the IFN-α pathway affected by
HTLV-1. The lack of HTLV-1 inhibition of IFN-α-stimulated
IRF1 expression suggests that cell surface presentation of
IFN-αR1 and IFN-αR2 and IFN-α binding is not perturbed by
HTLV-1. This is consistent with a previous report (Yokosawa
et al., 1997). Immunoblot studies showed that HTLV-1 did not
have an effect on total JAK1, TYK2, STAT1, and STAT2 protein
levels (Fig. 5). The lack of effects on synthesis of these proteins
despite the effects of HTLV-1 on their mRNA levels (Table 1) is
likely due to our experimental conditions in which protein levels
were examined after only 1 h andRNA levelswere examined after
4 h of IFN-α treatment. Nevertheless, HTLV-1 had significant
effects on TYK2 and STAT2 phosphorylation, and possibly, to a
lesser extent on JAK1 and STAT1 phosphorylation. This may be
mediated by the effects of HTLV-1 on JAK1, TYK2, STAT1, or
STAT2 association with the IFN-α receptor, activation of JAK/
STAT by the receptor, or dephosphorylation of JAK/STAT
(Fig. 5). However, we cannot exclude the possibility that HTLV-1
has additional and distinct repressive roles in the IFN signaling
pathway (Mordechai et al., 1995; Yamagata et al., 1996).
These findings may be applicable to the therapeutic uses of
IFN in infected individuals, or to endogenous IFN expression
during innate immune defenses against HTLV infection. Further
examination of the mechanism of HTLV-1 inhibition of signaling
by IFN-α, and methods to overcome IFN-α-resistance may im-
prove therapy forHTLV-1, and perhaps other retrovirus infections.
Materials and methods
Cell culture and reagents
293T and HeLa cells were cultured in Dulbecco's minimal
essential medium (DMEM) containing 10% fetal clone III (Hy-
clone, Logan, UT), 2% glutamine, and 100 U/ml penicillin and
100 μg/ml streptomycin. Recombinant human IFN-α-2a was
purchased from PBL Biomedical Laboratories. All antibodies
were purchased from Santa Cruz Biotechnology, except anti-
phoshotyrosine STAT2 (pSTAT2) was from Upstate Cell Sig-
naling Solutions (Lake Placid, NY).
Luciferase reporter assays
HeLa or 293T cells, 200 μl, 5–6×104 cells/ml, were seeded
into a 96-well plate for 16 h, and then transfected with 6.25 ng
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125 ng of pACH or backbone pBluescript-KS (Stratagene), or
mutant pACH plasmids, pACH-M22, pACH-M47, pACH-Env,
or pACH-Pol using TransIt-LT1 (Mirus Corp, Madison WI),
according to the manufacturer's complete growth medium pro-
tocol (Feng et al., 2003; Kimata et al., 1994; Robek and Ratner,
1999; Tsukahara and Ratner, 2001). After 72 h, cells were
treated with IFN 500–1000 U/ml for 6 h, and then lysed for
5–10 min at 20 °C with 100 μl of luciferase lysis buffer (Pro-
mega, Madison, WI). Cell lysates were measured for luciferase
activity according to the manufacturer's protocol.
Western blot analysis
pACH or pBluescript-KS was transfected into HeLa cells in a
6-well plate with 2 μg of DNA or into a 10-cm plate with 10 μg
DNA for 72 h, and then cells were treated with IFN-α for 1 h.
Cells were lysed in RIPA buffer containing protease inhibitor
cocktail (50mMHEPES, pH 7.5, 150mMNaCl, 1% (v/v) Triton
X-100, 10% glycerol, 1.5 mM MgCl2, 1 mM EDTA, 100 mM
NaF, 1 μg/ml aprotinin, 10 μg/ml pepstatin, 10 μg/ml leupeptin,
1 mM sodium orthovanadate). Cell lysates were sonicated for
10 s for complete lysis. Cell lysates were quantified using the
Bradford assay (Bio-Rad Laboratories, Hercules, CA), and
samples were boiled for 5 min. About 100–150 μg of protein
were separated on 8–10% SDS–PAGE (8% for JAK1, TYK2,
pJAK1, and pTYK2) and transferred onto Immobilon P mem-
brane (Millipore Corp, Billerica,MA).Membraneswere blocked
for 1–2 h with TBST (25 mM Tris–HCl, 137 mM NaCl, 0.05%
Tween-20) containing 5% milk for all antibodies except for
pJAK1 and pTYK2 antibodies, in which case TBST containing
1%milk and 1% BSAwas used. The samples were incubated for
16 h at 20 °C with primary antibody. Membranes were washed
three times with TBST for 15 min each wash, incubated for 1 h at
20 °C with 1:200 to 1:4000 dilution of secondary antibodies
which were peroxidase-conjugated, followed by three washes
with TBSTas before, and then developed with SuperSignal West
Femto Maximum Sensitivity Substrate (Pierce Biotechnology,
Rockford, IL). Protein bands were visualized with a CCD Imag-
ing System (Alpha Innotech, San Leandro, CA).
Real-time RT–PCR for IFN-induced gene expression and
SuperArray gene profiles for JAK/STAT pathway
HeLa cells were transfected with pACH or pBluescript for
48 h, and the treated with 500 U/ml IFN-α for 4 h. Total cellular
RNAs were isolated with RNeasy mini kit (Qiagen) and further
treated with RNase-free DNase (Qiagen). A total of 3 μg of each
RNA sample was used as a template to make cDNA with RT2
profiler first strand kit (C-02, SuperArray, Frederick, MD) for
one 96-well PCR array plate. Both individual gene expression
and human JAK/STAT signaling pathway RT profiler PCR
arrays were performed based on real-time PCR using an iCycler
(Bio-Rad) with SYBR green PCR master mixes (PA-011) ac-
cording to the manufacturer's protocol. Individual gene expres-
sions were normalized with GAPDH (SuperArray). JAK/STAT
pathway gene expressions were measured using PCR assaycontaining a panel of 84 pre-dispensed gene-specific primers for
JAK/STAT pathway (APH-039A), plus five housekeeping genes
and three RNA and PCR quality controls. By performing real-
time PCR, relative expression was determined by normalizing
with housekeeping genes, and the fold changes were analyzed by
the ΔΔCt method using the template designated by the manu-
facturer (SuperArray). Changes of 4-fold or more were found to
be statistically significant by t-test ( pb .03), based on the repro-
ducibility of the assay reported by the manufacturer.
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